GLP1R and type 2 diabetes mellitus: Moreover, one study has shown that a GIP-oxyntomodulin hybrid peptide (targeting GIP, GLP-1 and glucagon receptors) had beneficial effects on bone loss in db/db mice with T2DM (36).